Market Closed - Nasdaq 04:00:00 2024-07-05 pm EDT 5-day change 1st Jan Change
15.53 USD +4.30% Intraday chart for CareDx, Inc 0.00% +29.42%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
CareDx, Inc(NasdaqGM:CDNA) added to Russell 3000 Growth Index CI
CareDx, Inc(NasdaqGM:CDNA) added to Russell Microcap Growth Index CI
CareDx, Inc(NasdaqGM:CDNA) added to Russell 3000E Growth Index CI
CareDx, Inc(NasdaqGM:CDNA) added to Russell 2000 Growth Index CI
CareDx, Inc(NasdaqGM:CDNA) added to Russell 2500 Growth Index CI
CareDx, Inc(NasdaqGM:CDNA) added to Russell Small Cap Comp Growth Index CI
Transcript : CareDx, Inc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 04:00 PM
CareDx, Inc Announces New Data to Be Presented At the 2024 American Transplant Congress CI
Craig-Hallum Adjusts Price Target on CareDx to $22 From $15, Maintains Buy Rating MT
Study Shows CareDx, Inc.?s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies CI
Raymond James Downgrades CareDx to Market Perform From Outperform MT
Stephens Adjusts Price Target on CareDx to $18 From $15, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
CareDx Shares Rise After Q1 Results Beat Estimates MT
Earnings Flash (CDNA) CAREDX Reports Q1 Revenue $72M, vs. Street Est of $63.1M MT
Transcript : CareDx, Inc, Q1 2024 Earnings Call, May 09, 2024
CareDx, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CareDx Raises Revenue Guidance for the Year 2024 CI
North American Morning Briefing : Stock Futures -3- DJ
CareDx Appoints John Hanna as CEO, President MT
CareDx, Inc Appoints John W. Hanna as Chief Executive Officer CI
CareDx, Inc Appoints John W. Hanna as President and Member of the Board of Directors CI
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed RE
CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors CI
Transcript : CareDx, Inc, Q4 2023 Earnings Call, Feb 28, 2024
Chart CareDx, Inc
More charts
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
15.53 USD
Average target price
17.75 USD
Spread / Average Target
+14.29%
Consensus
  1. Stock Market
  2. Equities
  3. CDNA Stock
  4. News CareDx, Inc
  5. CareDx Shares Rise After Q1 Results Beat Estimates